BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jan 03, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

M2e/NP-ISS: Preliminary Phase Ia data

Preliminary data from a placebo-controlled, North American Phase Ia trial in 39 healthy volunteers showed that 3 doses of N8295 were well tolerated with no dose-limiting toxicities reported. Additionally, positive antibody responses to M2e and positive T cell mediated responses to NP were...

Read the full 195 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >